WHO recommends Merck COVID-19 pill for non-severe, at-risk patients

By: 3 years ago

Thailand and Indonesia unveil plans to develop molnupiravir COVID-19 pill

聽An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters on October 26, 2021. Merck & Co Inc/Handout via REUTERS

PARIS 鈥� The World Health Organization on Wednesday recommended an anti-Covid pill be taken by sufferers who have mild symptoms but are at high risk of hospitalization, such as older people or the unvaccinated.

The pill, called molnupiravir and developed by US pharmaceutical Merck, is taken as soon as possible after Covid-19 symptoms develop and then for the following five days.

A WHO group of experts said in the British Medical Journal that people with weak immune systems or chronic disease were also recommended to take the pill if they had non-severe Covid.

However 鈥測oung and healthy patients, including children, and pregnant and breastfeeding women should not be given the drug due to potential harms,鈥� they said.

The UN agency鈥檚 new recommendation was based on the results of six randomized controlled trials involving 4,796 patients, the 鈥渓argest dataset on this drug so far鈥�.

The trials suggested that molnupiravir reduced the risk of going to hospital, with 43 fewer admissions per 1,000 high-risk patients, as well as speeding up the pace at which symptoms cleared up by an average of 3.4 days.

There was less indication it had an affect on mortality, with just six fewer deaths per 1,000 patients.

The WHO acknowledged 鈥渢hat cost and availability issues associated with molnupiravir may make access to low- and middle-income countries challenging and exacerbate health inequity鈥�.

While vaccines remain the foremost tools in the fight against the pandemic, experts have welcomed the addition of the new oral treatments, which inhibit the virus鈥� ability to replicate and should withstand variants.

The only other main anti-Covid pill available is Pfizer鈥檚 Paxlovid.

However more potential concerns have been raised about Merck鈥檚 pill, which the US Food and Drug Administration has not authorised for under-18s because it could affect bone and cartilage growth.

黑料社